Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 6/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 3/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | ULK1 | O75385 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28733697 | 0.87 | VCP (0.40) | MAP2K1MAP2K2PRKCZIARS2ALOX5 | |
| SCHEMBL29620865 | 0.87 | VCP (0.40) | MAP2K1MAP2K2PRKCZIARS2ALOX5 | |
| SCHEMBL22925647 | 0.87 | VCP (0.40) | MAP2K1MAP2K2PRKCZIARS2ALOX5 | |
| SCHEMBL22925767 | 0.85 | MAOB (0.39) | MAP2K1NTRK1 | |
| SCHEMBL22925620 | 0.85 | ALOX5 (0.47) | MAP2K1ALOX5GCGRULK1 | |
| SCHEMBL29620962 | 0.85 | ALOX5 (0.47) | MAP2K1ALOX5GCGRULK1 | |
| SCHEMBL28733627 | 0.85 | ALOX5 (0.47) | MAP2K1ALOX5GCGRULK1 | |
| Hydrochloric Acid SCHEMBL29620914 | 0.84 | MAOB (0.38) | MAP2K1NTRK1 | |
| Hydrochloric Acid SCHEMBL28733689 | 0.84 | MAOB (0.38) | MAP2K1NTRK1 | |
| SCHEMBL22925698 | 0.84 | SCN9A (0.36) | NTRK1GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | Cincera Therapeutics Pty Ltd (AU) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220274970-A1 | INHIBITOR COMPOUNDS | SERPINB1, MMP1, SSB | MAP2K1 2869/4885NTRK1 4716/4885MAP2K2 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.